

COMMUNITY-ACQUIRED PNEUMONIA IN PEDIATRIC PATIENTS

ABSTRACT

Community-acquired pneumonia (CAP) remains a significant cause of morbidity and mortality in pediatric patients worldwide. Epidemiological studies reveal variations in the incidence and prevalence of CAP among different age groups, geographic locations, and socioeconomic backgrounds. Various pathogens, including bacteria, viruses, and atypical organisms, contribute to the development of CAP in children, with *Streptococcus pneumoniae* being the most common bacterial cause. Clinical presentation can range from mild respiratory symptoms to severe respiratory distress, necessitating hospitalization and intensive care. Diagnosis relies on a combination of clinical assessment, radiological findings, and microbiological tests, although challenges persist in distinguishing viral from bacterial etiologies. Management involves appropriate antimicrobial therapy, supportive care, and consideration of vaccination status. However, rising antimicrobial resistance poses challenges in treatment selection, emphasizing the importance of reasonable antibiotic use. Prevention strategies, including vaccination against common pathogens and promotion of hygiene measures, play a crucial role in reducing the burden of CAP in pediatric populations. Overall, a multidisciplinary approach involving pediatricians, infectious disease specialists, radiologists, and public health officials is essential for effectively managing and preventing CAP in children. Further research is needed to address emerging pathogens, optimize diagnostic strategies, and refine treatment guidelines to improve outcomes in pediatric patients with CAP. This abstract provides a comprehensive review of the epidemiology, etiology, clinical presentation, diagnosis, management, and prevention strategies

related to CAP in children. It will help understand the ever-changing trends in the field of child-care that come with the prevalence of pneumonia in pediatric patients.

Keywords: pneumonia, pediatric patients, community-acquired, respiratory infections, treatment of pneumonia.

INTRODUCTION

Community-acquired pneumonia (CAP) represents a significant burden on pediatric health worldwide, particularly affecting children under the age of five. (1)

In recent epidemiological studies, the incidence of first-episode pneumonia among unimmunized children in this age group has been reported at a staggering rate of 55.9 cases per 1000 person-years. This statistic underscores the pressing need for a thorough understanding of CAP in pediatric populations.(2)

Moreover, regional disparities exist in the incidence and prevalence of pediatric CAP. For instance, in Canada, an estimated 41,000 children under the age of five experience non-hospitalized CAP annually, while approximately 9600 require hospitalization for more severe cases. (3) Such findings highlight the varied impact of CAP across different geographic locations and healthcare settings.

One of the challenges in diagnosing CAP in pediatric patients lies in the diversity of its etiology. While various pathogens, including bacteria, viruses, and atypical organisms, contribute to the development of pneumonia, determining the specific cause can be elusive in clinical practice. (4)

However, age serves as a crucial clue for healthcare providers, guiding further investigation into the potential presence of pneumonia in young patients. (5)

The clinical presentation of pediatric CAP can range from mild respiratory symptoms to severe respiratory distress, necessitating hospitalization and intensive care. Timely and accurate

diagnosis is essential for appropriate management and prevention of complications associated with CAP in children. (6)

In addition to diagnostic challenges, the management of pediatric CAP is complex, requiring a multidisciplinary approach. Antimicrobial therapy, supportive care, and consideration of vaccination status are integral components of treatment strategies. However, the emergence of antimicrobial resistance poses significant challenges in selecting appropriate antibiotics and underscores the importance of reasonable antibiotic use in pediatric patients with CAP. (7)

Prevention strategies play a crucial role in reducing the burden of CAP in pediatric populations. Vaccination against common pathogens, such as *Streptococcus pneumoniae* and influenza viruses, is key to preventing pneumonia in children. (8) Furthermore, promoting hygiene measures, including handwashing and respiratory etiquette, can help minimize the spread of respiratory infections in community settings. (9)

Community-acquired pneumonia (CAP) poses a considerable challenge to pediatric health globally, particularly impacting children under five years old. (10) Recent epidemiological studies reveal a striking incidence rate of 55.9 cases per 1000 person-years among unimmunized children in this age bracket, highlighting the urgency for a comprehensive understanding of CAP within pediatric populations. (11)

Notably, regional variations in CAP incidence and prevalence underscore the diverse impact of the disease across different geographical and healthcare contexts. In Canada, for instance, an estimated 41,000 children under five experience nonhospitalized CAP annually, with approximately 9600 requiring hospitalization for more severe cases. (12)

Bacteria, viruses, and atypical organisms all play a role, complicating specific cause determination in clinical practice. Nonetheless, age serves as a pivotal indicator for healthcare providers, guiding further assessment of pneumonia in young patients. (13)

The clinical spectrum of pediatric CAP spans from mild respiratory symptoms to severe respiratory distress necessitating hospitalization and intensive care. Accurate and prompt diagnosis is crucial for effective management and prevention of CAP-related complications in children. (14)

Managing pediatric CAP entails a multidisciplinary approach, incorporating antimicrobial therapy, supportive care, and vaccination status consideration. However, the emergence of antimicrobial resistance presents challenges in selecting appropriate antibiotics, emphasizing the importance of prudent antibiotic use in pediatric CAP cases. (15)

Preventive strategies play a vital role in alleviating the burden of CAP in pediatric populations. Vaccination against common pathogens such as *Streptococcus pneumoniae* and influenza viruses is pivotal in preventing pneumonia in children. Moreover, promoting hygiene practices, including hand washing and respiratory etiquette, can mitigate the spread of respiratory infections within communities. (16)

THE PREVALENCE AND RECOGNITION OF COMMUNITY ACQUIRED PNEUMONIA IN CHILDREN

Historically, the World Health Organization (WHO) has relied on tachypnea as a primary indicator for diagnosing pneumonia, emphasizing sensitivity to ensure timely treatment with oral antibiotics.

This approach aimed to prevent missing cases of pneumonia in settings where delayed diagnosis could increase mortality rates. However, recent observational studies, particularly one conducted in four Indian hospitals, have highlighted potential shortcomings in this strategy. (17)

In the aforementioned study, 516 children initially diagnosed with pneumonia according to WHO criteria were reevaluated by pediatricians four days later. Surprisingly, only 35.9% of these children were confirmed to have pneumonia upon reassessment. The majority were reclassified with alternative conditions, including wheezing (42.8%), mixed respiratory diseases (18.6%), and nonrespiratory illnesses (2.7%). These findings suggest that the WHO's reliance on tachypnea alone may lead to overdiagnosis of pneumonia and subsequent unnecessary antibiotic use. (18)

Furthermore, this approach fails to distinguish between different pulmonary pathologies, potentially contributing to the overuse of antibiotics. Research conducted in low-income countries has demonstrated the tendency to overdiagnose pneumonia in cases presenting with wheezing. Consequently, there is a risk of underdiagnosing conditions such as asthma, leading to significant respiratory morbidity and, in severe cases, mortality. (19)

These findings further elaborated and highlighted the need for a more nuanced approach to diagnosing pediatric pneumonia, one that considers a broader range of clinical indicators and takes into account the potential overlap with other respiratory conditions.

By improving diagnostic accuracy, healthcare providers can avoid unnecessary antibiotic use, minimize the risk of antimicrobial resistance, and ensure appropriate management of respiratory illnesses, thus optimizing patient outcomes. (20)

In the modern day practice and in relation with the updated guidance from the World Health Organization (WHO) regarding community-acquired pneumonia (CAP) in children, there is a

valuable approach to optimizing antibiotic therapy through the use of simple clinical signs. (21) Specifically, children aged 2 to 59 months presenting with cough and/or difficulty breathing can receive oral amoxicillin if no red flag signs are present. These red flag signs include inability to drink, persistent vomiting, seizures, lethargy, reduced consciousness, stridor, or severe malnutrition. (22)

In industrialized countries, access to chest X-rays (CXR) as a diagnostic tool is more readily available, especially for children admitted to hospitals. CXR findings such as consolidation, infiltrates, and air bronchograms, whether in a lobar or diffuse pattern, play a crucial role in confirming the diagnosis of pneumonia and ruling out complications like pleural effusion, necrotizing pneumonia, or alternative diagnoses such as cardiac failure with pulmonary edema. (23)

However, the utility of chest radiography in community settings is limited, particularly for ambulatory patients. Clinical signs and chest radiography often show poor agreement in these cases, leading to a lack of routine CXR recommendation in suspected childhood CAP patients managed outside hospital settings according to British Thoracic Society (BTS) guidelines. (24)

Efforts have been made to bridge this diagnostic gap, particularly in resource-limited settings, by correlating clinical findings with radiological evidence of pneumonia. Studies conducted in the United Kingdom and the United States suggest that tachypnea exhibits the strongest correlation with radiographic evidence of pneumonia. Additionally, the presence of additional symptoms such as dyspnea/hypoxia or fever/hypoxia may further increase sensitivity in diagnosing pediatric pneumonia. (25)

While CXR remains a valuable diagnostic adjunct in hospitalized children with suspected CAP, its routine use in community-managed cases is not recommended due to limited agreement with

clinical signs. Instead, efforts should focus on developing improved clinical tools that correlate with radiological evidence, particularly in resource-poor settings, to ensure accurate diagnosis and appropriate management of pediatric CAP. (26)

FUTURE INSIGHTS AND PROGRESS FOR THE DIAGNOSTIC INTERVENTIONS OF COMMUNITY ACQUIRED PNEUMONIA IN CHILDREN

The introduction of nucleic acid-based detection methods has revolutionized the microbiological diagnosis of community-acquired pneumonia (CAP), marking a significant advancement in understanding and combating this respiratory illness. (27)

However, future research endeavors are imperative to separate the dynamics of viral and bacterial colonization in the respiratory tract and the implications of detecting multiple viral agents in CAP pathogenesis. Of particular interest is the comparison between consecutive and simultaneous detection of multiple pathogens, shedding light on their respective roles in disease progression. (28)

The global landscape of CAP epidemiology is evolving, propelled by increased vaccine coverage against pathogens such as *Haemophilus influenzae* type b and *Streptococcus pneumoniae*. Consequently, there is a notable shift in the epidemiology of bacterial CAP, with viruses emerging as a substantial causative agent. In light of this, there is a pressing need for point-of-care (POC) tests capable of accurately distinguishing between viral and bacterial pneumonia. (29)

Despite their promise, widespread implementation of these POC tests faces challenges, particularly in resource-constrained settings or primary care settings. High upfront costs and the need for complex sample preparation to mitigate PCR inhibition present significant barriers to accessibility and utility. Addressing these challenges is crucial to ensure the availability and

effectiveness of POC tests for pneumonia diagnosis, ultimately improving patient outcomes and reducing the burden of CAP on global health. (30)

The advancement of novel amplification technologies is paramount in overcoming the limitations associated with current diagnostic methods for pneumonia. A notable innovation in this regard is the loop-mediated isothermal amplification (LAMP) method, which obviates the need for thermal cycling during sample amplification. This method offers several advantages over PCR, including a simplified procedure, reduced time to detection, and the use of more compact and cost-effective detection equipment. (31)

Recent developments in LAMP technology have yielded promising results, with several assays demonstrating performance comparable to PCR. For instance, LAMP assays for detecting pathogens such as *Streptococcus pneumoniae*, group B *Streptococcus*, and pertussis have been successfully validated. Notably, a pertussis LAMP assay exhibited a detection speed 2.5 times faster than real-time PCR, with a sensitivity of 96.55% and specificity of 99.46%. (32)

The versatility and efficacy of LAMP technology render it particularly valuable in point-of-care microbiology, especially in resource-limited settings. However, further optimization is necessary to enhance sensitivity, particularly in respiratory virus detection, and to enable the simultaneous detection of multiple pathogens. Continued research and development efforts in this direction hold the potential to significantly improve pneumonia diagnosis and management, ultimately benefiting patient care and public health outcomes. (33)

CONCLUSION

Community-acquired pneumonia (CAP) diagnosis and management is undergoing a transformative shift driven by advancements in nucleic acid-based detection methods and the development of novel amplification technologies. The integration of these innovative approaches

holds promise for improving the accuracy, efficiency, and accessibility of pneumonia diagnosis, particularly in resource-limited settings and primary care settings. The World Health Organization's updated guidance on CAP recognition underscores the importance of simple clinical signs in directing optimal antibiotic therapy, while also highlighting the need for point-of-care tests capable of differentiating between viral and bacterial pneumonia. As such, the loop-mediated isothermal amplification (LAMP) method emerges as a promising alternative to traditional PCR, offering simplified procedures, reduced time to detection, and cost-effective equipment. While significant strides have been made in validating LAMP assays for various pathogens, further research is essential to optimize sensitivity, especially in respiratory virus detection, and to enable the simultaneous detection of multiple pathogens. These advancements have the potential to revolutionize pneumonia diagnosis and management, ultimately leading to improved patient outcomes and reduced disease burden on a global scale.

REFERENCES

1. Rodrigues CMC, Groves H. Community-Acquired Pneumonia in Children: the Challenges of Microbiological Diagnosis. *J Clin Microbiol*. 2018 Feb 22;56(3):e01318-17.
2. Davies HD. Community-acquired pneumonia in children. *Paediatr Child Health*. 2003 Dec;8(10):616-9.
3. Katz SE, Williams DJ. Pediatric Community-Acquired Pneumonia in the United States. *Infect Dis Clin North Am*. 2018 Mar;32(1):47-63.
4. Leung AKC, Wong AHC, Hon KL. Community-Acquired Pneumonia in Children. *Recent Pat Inflamm Allergy Drug Discov*. 2018;12(2):136-44.
5. Nascimento-Carvalho CM. Community-acquired pneumonia among children: the latest evidence for an updated management. *J Pediatr (Rio J)*. 2019 Sep 10;96(Suppl 1):29-38.
6. Smith DK, Kuckel DP, Recidoro AM. Community-Acquired Pneumonia in Children: Rapid Evidence Review. *Am Fam Physician*. 2021 Dec 1;104(6):618-25.
7. Tramper-Stranders GA. Childhood community-acquired pneumonia: A review of etiology- and antimicrobial treatment studies. *Paediatr Respir Rev*. 2018 Mar;26:41-8.

8. Alzomor O, Alhajjar S, Aljobair F, Alenizi A, Alodyani A, Alzahrani M, et al. Management of community-acquired pneumonia in infants and children: Clinical practice guidelines endorsed by the Saudi Pediatric Infectious Diseases Society. *Int J Pediatr Adolesc Med*. 2017 Dec;4(4):153–8.
9. Nascimento-Carvalho AC, Nascimento-Carvalho CM. Clinical management of community-acquired pneumonia in young children. *Expert Opin Pharmacother*. 2019 Mar;20(4):435–42.
10. Singla S, Sih K, Goldman RD. Antibiotic treatment duration for community-acquired pneumonia in children. *Can Fam Physician*. 2023 Jun;69(6):400.
11. Mi X, Li W, Zhang L, Li J, Zeng L, Huang L, et al. The drug use to treat community-acquired pneumonia in children. *Medicine (Baltimore)*. 2018 Nov 16;97(46):e13224.
12. Cardinale F, Cappiello AR, Mastrototaro MF, Pignatelli M, Esposito S. Community-acquired pneumonia in children. *Early Hum Dev*. 2013 Oct;89:S49–52.
13. Qian C, Chen Q, Lin W, Li Z, Zhu J, Zhang J, et al. Incidence of community-acquired pneumonia among children under 5 years in Suzhou, China: a hospital-based cohort study. *BMJ Open*. 2024 Jan 3;14(1):e078489.
14. Manikam L, Lakhanpaul M. Epidemiology of community acquired pneumonia. *Paediatr Child Health*. 2012 Jul;22(7):299–306.
15. Lokida D, Farida H, Triasih R, Mardian Y, Kosasih H, Naysilla AM, et al. Epidemiology of community-acquired pneumonia among hospitalised children in Indonesia: a multicentre, prospective study. *BMJ Open*. 2022 Jun 21;12(6):e057957.
16. Takeuchi N, Naito S, Ohkusu M, Abe K, Shizuno K, Takahashi Y, et al. Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan. *Epidemiol Infect*. 148:e91.
17. Gowraiah V, Awasthi S, Kapoor R, Sahana D, Venkatesh P, Gangadhar B, et al. Can we distinguish pneumonia from wheezy diseases in tachypnoeic children under low-resource conditions? A prospective observational study in four Indian hospitals. *Arch Dis Child*. 2014 Oct;99(10):899–906.
18. Østergaard MS, Nantanda R, Tumwine JK, Aabenhus R. Childhood asthma in low income countries: an invisible killer? *Prim Care Respir J J Gen Pract Airw Group*. 2012 Jun;21(2):214–9.
19. Revised WHO Classification and Treatment of Pneumonia in Children at Health Facilities: Evidence Summaries [Internet]. Geneva: World Health Organization; 2014 [cited 2024 Feb 23]. (WHO Guidelines Approved by the Guidelines Review Committee). Available from: <http://www.ncbi.nlm.nih.gov/books/NBK264162/>

20. Executive Summary. In: Revised WHO Classification and Treatment of Pneumonia in Children at Health Facilities: Evidence Summaries [Internet]. World Health Organization; 2014 [cited 2024 Feb 23]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK264164/>
21. Zar HJ, Moore DP, Andronikou S, Argent AC, Avenant T, Cohen C, et al. Diagnosis and management of community-acquired pneumonia in children: South African Thoracic Society guidelines. *Afr J Thorac Crit Care Med.* 2020 Oct 13;26(3):10.7196/AJTCCM.2020.v26i3.104.
22. Scientific basis of WHO recommendations for treatment of pneumonia. In: Revised WHO Classification and Treatment of Pneumonia in Children at Health Facilities: Evidence Summaries [Internet]. World Health Organization; 2014 [cited 2024 Feb 23]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK264159/>
23. Posten S, Reed J. Pediatric Community Acquired Pneumonia. *S D Med J S D State Med Assoc.* 2017 Dec;70(12):557–61.
24. Stuckey-Schrock K, Hayes BL, George CM. Community-acquired pneumonia in children. *Am Fam Physician.* 2012 Oct 1;86(7):661–7.
25. Kevat PM, Morpeth M, Graham H, Gray AZ. A systematic review of the clinical features of pneumonia in children aged 5-9 years: Implications for guidelines and research. *J Glob Health.* 12:10002.
26. Ebeledike C, Ahmad T, Martin SD. Pediatric Pneumonia (Nursing). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Feb 23]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK568682/>
27. Macpherson L, Ogero M, Akech S, Aluvaala J, Gathara D, Irimu G, et al. Risk factors for death among children aged 5–14 years hospitalised with pneumonia: a retrospective cohort study in Kenya. *BMJ Glob Health.* 2019 Sep 1;4(5):e001715.
28. McCollum ED, Ginsburg AS. Outpatient Management of Children With World Health Organization Chest Indrawing Pneumonia: Implementation Risks and Proposed Solutions. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2017 Oct 16;65(9):1560–4.
29. Jroundi I, Mahraoui C, Benmessaoud R, Moraleda C, Tligui H, Seffar M, et al. Risk factors for a poor outcome among children admitted with clinically severe pneumonia to a university hospital in Rabat, Morocco. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis.* 2014 Nov;28:164–70.
30. Principi N, Esposito S, Blasi F, Allegra L, Mowgli study group. Role of *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* in children with community-acquired lower respiratory tract infections. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2001 May 1;32(9):1281–9.

31. Kumar S. Mycoplasma pneumoniae: A significant but underrated pathogen in paediatric community-acquired lower respiratory tract infections. Indian J Med Res. 2018 Jan;147(1):23–31.
32. Schalock PC, Dinulos JGH. Mycoplasma pneumoniae-induced cutaneous disease. Int J Dermatol. 2009 Jul;48(7):673–80; quiz 680–1.
33. Lanao AE, Chakraborty RK, Pearson-Shaver AL. Mycoplasma Infections. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Feb 23]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK536927/>

UNDER PEER REVIEW